- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03845582
Phase 3 Study of ALK-001 in Geographic Atrophy (SAGA)
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).
Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.
Study Overview
Status
Intervention / Treatment
Detailed Description
There is no treatment available for Geographic Atrophy secondary to AMD. AMD is characterized by an age-related degeneration of the retina.
The root cause for this degeneration or why some people develop AMD while others do not, is unknown. Over 20 years ago, it was hypothesized that the dimerization of vitamin A may be a significant contributor to the etiology of AMD. The eye indeed uses vitamin A as a cofactor to sense light, and a striking chemical signature of the aging and degenerating retina is the accumulation of vitamin A dimers in the retinal pigment epithelium (RPE) and the underlying Bruch's membrane. In rodent models, high levels of vitamin A dimers correlate with poor retinal health, and a variety of mechanisms have been proposed by which vitamin A dimers may induce retinal toxicity. It has been argued that these mechanisms participate in the development and progression of AMD.
ALK-001, the study drug, is a modified form of vitamin A. When taken once a day as a capsule, it replaces natural vitamin A in the body with one that forms vitamin A dimers more slowly. This study will measure the extent to which treatment with ALK-001 slows the progression of Geographic Atrophy.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Somerville, Massachusetts, United States, 02144
- Coordinating Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Major Inclusion Criteria:
- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD)
Major Exclusion Criteria:
- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALK-001
Capsule
|
Daily administration for 24 months
Other Names:
|
Placebo Comparator: Placebo
Capsule
|
Daily administration for 24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Growth rate of GA lesions, as assessed by Fundus Autofluorescence (FAF)
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability, as assessed by evaluation of adverse events
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Pharmacokinetics, as assessed by plasma concentrations of ALK-001 and metabolites
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Incidence of choroidal neovascularization (CNV)
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Changes in Visual Acuity
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Changes in Reading Speed
Time Frame: Baseline to 24 months
|
Baseline to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Leonide Saad, PhD, Alkeus Pharmaceuticals, Inc.
Publications and helpful links
General Publications
- Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.
- Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D(3)-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.
- Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Pathological Conditions, Anatomical
- Macular Degeneration
- Geographic Atrophy
- Atrophy
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Adjuvants, Immunologic
- Vitamins
- Anticarcinogenic Agents
- Vitamin A
- Retinol acetate
Other Study ID Numbers
- ALK001-P3001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Geographic Atrophy
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States
-
GlaxoSmithKlineCompletedAtrophy, GeographicUnited States, Canada
-
GlaxoSmithKlineQuintiles, Inc.Completed
-
Carl Zeiss Meditec, Inc.DataMed Devices Inc.CompletedAdvanced Dry AMD With Geographic AtrophyUnited States
-
Apellis Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy Secondary to Age-related Macular DegenerationUnited States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
-
Boehringer IngelheimCompletedGeographic AtrophyUnited States
-
Genentech, Inc.Completed
-
Apellis Pharmaceuticals, Inc.CompletedGeographic AtrophyUnited States, Australia, New Zealand
-
Genentech, Inc.Completed
-
Alcon ResearchNovartis Institutes for BioMedical ResearchCompleted
Clinical Trials on ALK-001 oral capsule
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
AtoGen Co. LtdATOGEN AUSTRALIA PTY LTDRecruitingBacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial VaginosisAustralia
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyCompleted
-
Georgetown UniversityNational Institutes of Health (NIH)RecruitingDementia With Lewy BodiesUnited States